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Action potential duration dispersion
Background/objectives: Cardiac contractilitymodulation (CCM) is a new treatment being developed for heart fail-
ure (HF) involving application of electrical current during the absolute refractory period. We have previously
shown that CCM increases ventricular force through β1-adrenoceptor activation in the whole heart, a potential
pro-arrhythmic mechanism. This study aimed to investigate the effect of CCM on ventricular ﬁbrillation suscep-
tibility.
Methods: Experiments were conducted in isolated New Zealand white rabbit hearts (2.0–2.5 kg, n = 25). The
effects of CCM (±20 mA, 10 ms phase duration) on the left ventricular basal and apical monophasic action
potential duration (MAPD) were assessed during constant pacing (200 bpm). Ventricular ﬁbrillation threshold
(VFT) was deﬁned as the minimum current required to induce sustained VF with rapid pacing (30 × 30 ms).
Protocols were repeated during perfusion of the β1-adrenoceptor antagonist metoprolol (1.8 μM). In separate
hearts, the dynamic and spatial electrophysiological effects of CCM were assessed using optical mapping with
di-4-ANEPPS.
Results: CCM signiﬁcantly shortened MAPD close to the stimulation site (Basal: 102 ± 5 [CCM] vs. 131 ± 6
[Control] ms, P b 0.001). VFT was reduced during CCM (2.6 ± 0.6 [CCM] vs. 6.1 ± 0.8 [Control] mA, P b 0.01)
and was correlated (r2 = 0.40, P b 0.01) with increased MAPD dispersion (26 ± 4 [CCM] vs. 5 ± 1 [Control]
ms, P b 0.01) (n = 8). Optical mapping revealed greater spread of CCM induced MAPD shortening during
basal vs. apical stimulation. CCM effects were abolished bymetoprolol and exogenous acetylcholine. No evidence
for direct electrotonic modulation of APD was found, with APD adaptation occurring secondary to adrenergic
stimulation.
Conclusions: CCM decreases VFT in a manner associated with increased MAPD dispersion in the crystalloid
perfused normal rabbit heart.© 2014 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY license. ial duration; CCM, cardiac con-
hasic action potential duration
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Cardiac contractility modulation (CCM) is an electrical device thera-
py being developed for the treatment of heart failure (HF), which
remains a signiﬁcant clinical burden despite decades of research and
the development of useful drug therapy [1]. During CCM, electrical sig-
nals are applied to the ventricularmyocardium to increase force and are
timed to coincidewith the absolute refractory period. Experimental and
clinical studies demonstrate that CCM improves contractile perfor-
mance, increases patient exercise capacity and improves quality of life
(reviewed by Winter et al. [2]). Several studies have highlighted that
CCM reverses the molecular remodelling associated with heart failure
opposing the down-regulation of several calcium handling proteins
(e.g. phospholamban, sarco-endoplasmic reticulum ATPase (SERCA)),nse. 
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uretic peptide) and ﬁbrosis, which may contribute to its long term
beneﬁcial action [2,3].
We have previously demonstrated that the acute effects of CCM are
mediated via stimulated norepinephrine (NE) release resulting in cardi-
ac β1-adrenoceptor activation and shortening of locally recorded
monophasic action potential duration (MAPD); in the crystalloid per-
fused normal rabbit heart [4]. The adrenergic dependence of CCM raises
interesting questions regarding its neuro-cardiac action and the poten-
tial pro-arrhythmic nature of induced electrophysiological changes.
Efferent and afferent sympathetic and parasympathetic nerves richly
innervate the cardiac ventricle and it has long been known that afferent
nerves relay sensory information from the myocardium to the intra-
cardiac and intra-thoracic ganglia, spinal cord and the brain for integra-
tion to regulate cardiac function [5]. It is recognised that local reﬂexes,
acting through the cardiac and intra-thoracic ganglia, can modulate
cardiac function on a beat-to-beat basiswithout involvement of the cen-
tral nervous system [6]. It is perceivable that CCM captures both afferent
and efferent nerveﬁbres, and that the former could engage intrathoracic
ganglia or reﬂex activated sympathetic preganglionic neurones in the
spinal cord. Furthermore, CCM may release acetylcholine (ACh) from
parasympathetic nerves within the ventricle. ACh is known to
antagoniseNE synaptic release and antagonise post-synaptic adrenergic
signalling and so it is necessary to establish whether ACh has a role in
acute action of CCM (i.e. does ACh modulate the adrenergic component
of CCM?).
It has long been acknowledged that adrenergic activation is pro-
arrhythmic.Wehave previously shown that sympathetic nerve stimula-
tion increases the susceptibility of the heart to ventricular ﬁbrillation
(VF) [7]. Given the adrenergic dependence of CCM and the pro-
arrhythmic effect of positive inotropic drugs in HF, it is important to
determine the effects of CCM on ventricular arrhythmia susceptibility
[8].
The aims of this study were to investigate: 1) the role of pre and
post-ganglionic signalling in CCM, 2) any role for ACh in modulating
the acute ventricular response to CCM and 3) the effects of CCM on
ventricular electrophysiology and arrhythmia susceptibility.
2. Methods
2.1. Animal welfare and ethical publishing declaration
Experiments were conducted on Adult male New Zealand White rabbit hearts
(2.5–3.5 kg, n = 22), using the non-innervated and innervated heart preparations. All
procedures were undertaken in accordance with ethical guidelines set out by the UK
Animals (Scientiﬁc Procedures) Act 1986 and conformed to the Guide for the Care and
Use of Laboratory Animals Published by the US National Institutes of Health (NIH Publica-
tion No. 85-23, revised 2010).
The author(s) of thismanuscript have certiﬁed that they complywith the Principles of
Ethical Publishing in the International Journal of Cardiology.
2.2. Isolation of the non-innervated heart preparation
Adult male New Zealand White rabbit hearts were isolated as previously described
[4]. In brief, animals were pre-medicated with ketamine (Ketaset, 10 mg/kg, Fort Dodge,
UK), medetomidine hydrochloride (Sedator, 0.2 mg/kg, Dechra, UK) and butorphanol
(Torbugesic, 0.05 mg/kg, Fort Dodge, UK) (i.m.). Following stable sedation, animals were
sacriﬁced with an overdose of pentobarbitone sodium (Sagatal, Rhone Merieux, UK;
111 mg/kg body weight, i.v.) containing Heparin (1000 IU, Multiparin, UK) delivered via
themarginal ear vein. The hearts were rapidly excised, placed into ice cold tyrode solution
to reducemetabolic rate and retrogradely perfused through the ascending aorta in condi-
tions of constant ﬂow Langendorff mode (40 ml/min) using a GilsonMinipuls 3 peristaltic
pump (Anachem, UK).
2.3. Isolation of heart with intact autonomic innervation
The innervated Langendorff perfused isolated heart preparationwas utilised as previ-
ously described [9]. An illustration of the preparation can be found in Fig. 1B. In brief, fol-
lowing pre-medication, anaesthesia was maintained with i.v. propofol (5 mg as required,
Rapinovet, Schering-Plough Animal Health, UK) for the remainder of surgery. Following
tracheotomy animals were ventilated with room air using a small animal ventilator (Har-
vardApparatus Ltd, UK; 60breaths/min). The left and right vagus nerveswere isolated, andthe bloodvessels leading to and from the ribcagewere ligated anddissected. Animalswere
sacriﬁced with an overdose of pentobarbitone sodium containing heparin (as above). The
anterior portion of the ribcage was removed, and the descending aorta was cannulated.
The pericardium was cut, and ice-cold Tyrode solution was applied to the surface of the
heart. The preparation, extending from C1 to T12 vertebrae, was dissected from surround-
ing tissues and perfused through the descending aorta (100 ml/min) [9].
2.4. Solutions
Hearts were perfused with Tyrode solution of the following composition (mM):
Na+ 138.0, K+ 4.0, Ca2+ 1.8, Mg+ 1.0, HCO3− 24.0, H2PO4− 0.4, Cl− 121.0, glucose
11.0 and acetate 20.0. The solution was continuously bubbled with 95% O2–5% CO2
to maintain a constant pH of 7.4. Temperature was maintained at 37 °C. A 3 F poly-
propylene catheter (Portex, UK) was inserted at the left ventricular (LV) apex for
drainage of Thebesian venous efﬂuent.
2.5. Functional parameters
Intra-ventricular LV pressure (LVP) was measured with a ﬂuid-ﬁlled latex balloon
connected to a pressure transducer (MTL0380, ADInstruments Ltd, UK) inserted into the
LV via the left atrium. LV end diastolic pressure was maintained between 0 and 5 mm
Hg. Aortic perfusion pressure (PP) was monitored with a second pressure transducer
connected in series to the aortic cannula.
2.6. Cardiac electrical recording and pacing
MAP-TIP recording catheters (73-0150, Harvard Apparatus, UK), with a tip diameter
of 1.5 mm electrode spacing of 4 mm, were used to record action potentials from the
epicardial surface of the LV using aDC-coupledhigh input impedance differential ampliﬁer
(Joint Biomedical Workshop, University of Leicester, UK). MAPs were recorded from the
LV epicardium at apical and/or basal sites depending on the experimental protocol.
Pacing electrode locations are illustrated on Fig. 1A. Endocardial pacing electrodes
were inserted through the pulmonary trunk or left atrial appendage for RV and LV apical
endocardial pacing, respectively (electrode diameter = 2 mm, spacing = 4 mm). For
epicardial pacing, a pair of platinum hook electrodes (spacing = 4 mm) were inserted
into the basal anterior LV freewall. Pacing stimuli delivered using a constant current
electrical stimulator (DS7A, Digitimer Ltd, UK).
2.7. CCM signal generation and delivery
Square wave electrical pulses were generated using a Neurolog modular system
(Digitimer, UK) with signals delivered using a constant current stimulator (Model A385,
World Precision Instruments, UK). CCM stimuli were triggered using the pacing stimulus
as previously described [4]. CCM signal were applied to the epicardial surface of the LV
through a pair of platinumhook electrodes (inter-electrode distance ~ 1 cm) as a biphasic
waveform with equal positive and negative phase amplitudes (stimulus amplitude = 20 mA
and phase duration = 10 ms). We have previously demonstrated that these parameters
induce optimal responses [4]. CCM signals were timed to coincide with the plateau
phase using a locally recorded MAP (see Fig. 1.) and were delivered 2–3 min, allowing
for a 30 second period of steady state. A 10–15 minute rest period between stimulations
was used throughout the experiment for parameters to return to baseline. Hearts were
paced during all CCM protocols at a 300 ms cycle length.
2.7.1. Protocols
2.7.1.1. Role of the intracardiac/intrathoracic ganglia. The effects of CCM on ventricular and
electrophysiological performance were assessed in the innervated Langendorff heart in the
absence and presence of the nicotinic ACh channel antagonist hexamethonium (0.5 mM)
[10]. Ganglionic blockade was conﬁrmed by inhibition of bradycardia with right vagus
nerve stimulation (5Hz, 5 V). CCM was applied in basal regions of the LV.
2.7.1.2. Role of ACh. The effects of CCMon ventricular and electrophysiological performance
were assessed in the non-innervated Langendorff heart preparation in the absence (Control)
and presence of;
A. The muscarinic ACh receptor antagonist atropine (0.1 mM) [10].
B. Exogenous ACh (1 μM) [13] with and without atropine (0.1 μM) [11].
2–3 stimulations were conducted at baseline and during perfusion. The order of per-
fusion was randomised from heart to heart to reduce any bias. CCM was applied in basal
regions of the LV.
2.7.1.3. VFT, ERP and APD dispersion
2.7.1.3.1. VFT. The susceptibility of the heart to VF was studied by measuring the
ventricular ﬁbrillation threshold (VFT) in the non-innervated Langendorff heart. VFT was
obtained by RV endocardial, LV endocardial or LV epicardia pacing using a train of
30-stimuli (CL = 30 ms, 2 ms pulse width) spanning the refractory period following
a 20-beat S1 drive train (CL= 300 ms, 2 ms pulse width) and determined by progres-
sively increasing the pacing current (0.5 mA steps), with 2-second rest period before
the next pacing train if no VF was induced (see Fig. 2). VFT was deﬁned as the mini-
mum current required to induce sustained VF. VFT was assessed in the absence and
Fig. 1. CCM signal delivery and the isolated innervated rabbit heart. A) Illustration of heartwith pacing, recording and CCM stimulation sites. A squarewave bipolar signal is applied directly
to the surface of the left ventricle (LV) during the absolute refractory period. Signals were applied to either basal or apical regions of the LV epicardium depending upon the experimental
protocol. Hearts were paced at a cycle length of 300 ms. Monophasic action potentials (MAP) were recorded in both basal and apical regions. B) Illustration of isolated innervated
Langendorff rabbit heart preparation. Key: LA = left atrium, LVP = left ventricular pressure, PP = perfusion pressure, RAEG = right atrial electrogram, RA = right atrium, RVNS =
right vagus nerve stimulation, RV = right ventricle.
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a minimum period of 60 s during constant pacing (CL = 300 ms) before commenc-
ing the VFT protocol. During VFT protocol, CCM was applied during the S1 beats
but not during the rapid pacing period of the VF protocol. VF was terminated using
a 2–3 ml bolus injection of 50 mM KCL. Hearts were allowed to beat intrinsically be-
tween protocols, allowing for a 10-minute recovery period before initiation of pacing.
A 5-minute period was allowed for the stabilisation of MAPD before commencement
of each protocol. In separate hearts, the effects of CCM on VFT were repeated during
perfusion of the β1-adrenoceptor antagonist Metoprotol (1.8 μM) [4,9]. Baseline,
Basal CCM and Apical CCM data reﬂects the average of 3 VFT repeats at each steady
state during the experimental protocols, in each heart. The order of pacing was
randomised in each experiment.
2.7.1.3.2. Effective refractory period. Theeffective refractory period (ERP)was estimated
using an extra-stimulus protocol consisting of a 20-beat drive train (S1) at a constant CL
(300 ms) followed by an extra-stimulus (S2) at progressively shorter CLs (200 ms, 5 ms
steps). ERP was measured in RV endocardial, LV endocardial and LV epicardial regions
during basal and apical CCM. ERP was deﬁned as the longest S1-S2 interval that failed to
capture. Pacing stimuli were applied at twice the diastolic threshold current, with a
pulse width of 2 ms.2.7.1.3.3. MAPD dispersion. Ventricular MAPD dispersion was measured as the differ-
ence between in MAPD the two sites using contact electrodes (non-innervated hearts).
These data were obtained during the period of constant pacing (CL = 300 ms), prior to
the assessment of VFT, as described above, at baseline and during CCM delivery in basal
and apical regions.
2.7.1.4. AP dynamics and spatial effects of CCM (optical mapping). APs were recorded with
optical mapping of the anterior LV surface of the non-innervated rabbit heart
(18 × 18 mm). Optical action potentials (AP) were recorded following a bolus injection
of di-4 ANEPPS (40 μl, 1 mg/ml in DMSO, Invitrogen, USA). Hearts were illuminated
episcopically with an LED light source (535 nm). Emitted light was ﬁltered through a
630 nm long-pass ﬁlter and collected using a Hamamatsu 16 × 16 element photodiode
array (Cairn Research, Faversham, UK). Hearts were mechanically uncoupled with
blebbistatin (5 μM). Optical studies were conducted in the non-innervated rabbit heart.
2.7.1.4.1. APD dynamics. Experiments were performed to assess the dynamics to APD
change during CCM. Optical APs were recorded continuously at stable baseline (300 ms CL)
and during applications of biphasic CCM signals (±20 mA, 20 ms) to the LV free wall.
The effects of CCM on APD was assessed at regions within 2 mm of the stimulating elec-
trode and in APs with a clear deﬂection associated with CCM stimulation.
Fig. 2. Ventricular ﬁbrillation threshold protocol. VFTwas obtained by right ventricular pacing using a train of 30 stimuli (CL = 30 ms) spanning the refractory period following a 20-beat
drive train (CL = 300 ms) and determined by progressively increasing the pacing current in 0.5 mA steps, with a 2-second rest period before the next pacing train if no VF was induced.
VFT was deﬁned as the minimum current required inducing sustained VF. VFT was assessed in the absence and presence of CCM applied separately in basal and apical regions. CCM was
applied for a 60-second period during constant pacing (CL = 300 ms) before commencement of the protocol, and throughout the S1 drive train. CCMwas not applied during the 2-second
rest period between consecutive S1 drive trains or during the rapid pacing period.
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during constant pacing (CL = 300 ms). The degree of spread of APD shortening during
CCM was assessed from the site of CCM signal delivery (Base→ Apex or Apex→ Base).
Studies were conducted in the non-innervated rabbit heart.2.8. Signal measurements and analysis
Functional parameters and MAPs were recorded with a PowerLab 8 s system
and digitised at 2 kHz using Chart and Scope software (ADInstruments Ltd). Optical
AP signals were digitised at 2 kHz and recorded on a custom designed computer sys-
tem (National Instruments, USA) using QRecord software (Dr Francis Burton, Uni-
versity of Glasgow, UK). LV contractile performance was assessed from an average
of 20 cardiac cycles during baseline and subsequently during the steady state CCM
response. Contact MAPD was measured at 90% repolarisation (MAPD90) averaged
over 20-cardiac cycles recorded during steady state before and immediately on ces-
sation of CCM stimulation due to signal interference from the current used during
CCM. Optical APD90 was assessed before and during the steady state response to
CCM signal delivery as there was no signal interference from the current used dur-
ing CCM on the recorded APs. Both MAPD90 and optical APD90 calculations were per-
formed using custom written analysis software (NewMap and Optiq respectively,
Dr. F. Burton).2.9. Statistical methods
Statistical comparisons were made using Student's paired t-tests, one- or two-way
ANOVA where appropriate with Bonferroni post-hoc test. P b 0.05 was considered signif-
icant. All statistically signiﬁcant differences reported in thismanuscript represent a sample
size to give aminimumstatistical power of 0.94, at an alpha level of 0.05. Data are presented
as mean values ± standard error of the mean.3. Results
3.1. Role of intracardiac/intrathoracic ganglia
Data illustrating the effects of hexamethonium perfusion on the
acute ventricular response to CCM, in the innervated Langendorff heart,
are summarised in Fig. 3. Ganglionic blockade was conﬁrmed by the
abolition of right vagus nerve stimulation induced bradycardia
(Fig. 3A&B). In control, right vagus nerve stimulation reduced heart
rate by 76 ± 9 bpm and was abolished during perfusion with 0.5 mM
hexamethonium (Δ = −1 ± 1 bpm, n = 3). During hexamethonium
perfusion, CCM stimulated enhancement of LV pressure, maximal rate
of change of pressure and shortening of MAPD90 (Fig. 3C–E) were
comparable to control (n = 5).3.2. Role of ACh
3.2.1. Atropine
Perfusion of atropine had no effect on the increase in LVP
(Δ3.9 ± 0.7 [Atropine] vs. Δ4.2 ± 0.6 [Control] mm Hg), dP/dtmax
(Δ186 ± 47 [Atropine] vs. Δ175 ± 27 [Control] mm Hg/s) or MAPD90
shortening (Δ-27 ± 9 [Atropine] vs.Δ-28 ± 7 [Control] ms) associated
with CCM (n = 5), indicating no role for endogenous ACh release in the
acute ventricular effects of CCM.
3.2.2. Exogenous ACh
Raw and mean data illustrating the effect of exogenous ACh perfu-
sion on the acute effects of CCM are presented in Fig. 4. Exogenous
ACh inhibited the increase in peak LV pressure (Fig. 4B), maximal rate
of change of pressure (Δ126 ± 16 vs. Δ30 ± 4 mm Hg/s, P b 0.05)
and shortening of MAPD90 (Fig. 4C) associated with CCM (n = 4). The
inhibition of CCM with ACh was reversed during combined perfusion
with 0.1 μM atropine (Fig. 4, n = 4). Exogenous ACh perfusion caused
coronary vasodilation, evidenced by a reduction in PP (54.4 ± 10.9 vs.
50.9 ± 10.6 mm Hg, P b 0.05), but had no signiﬁcant effect on LVP or
MAPD90 in baseline conditions.
3.3. VFT, ERP and MAPD dispersion
3.3.1. VFT
Mean data on the effect of CCM on VFT are illustrated in Fig. 5A. CCM
was associated with a signiﬁcant reduction in VFT during RV (Fig. 5Ai)
and LV (Fig. 5 Aii) endocardial pacing, indicating increased susceptibility
to VF. Similarly CCM applied at basal regions, during LV epicardial pac-
ing, reduced VFTwith a borderline signiﬁcant trend associatedwith api-
cal CCM (Fig. 5Aiii, P = 0.06). Themagnitude change in VFTwith apical
and basal CCM was similar in all conditions, with the exception of LV
epicardial stimulation where there was a larger reduction in VFT during
basal vs. apical CCM (Fig. 5Aiii). Perfusion of metoprolol abolished the
reduction in VFT during basal (5.35 ± 0.8 [Basal CCM + Metoprolol]
vs. 5.4 ± 0.7 [Metoprolol] mA) and apical CCM (5.42 [Apical
CCM + Metoprolol] vs. 5.4 ± 0.7 [Metoprolol] mA) (RV endocardial
pacing, n = 6).
3.3.2. ERP
Changes in ERP were dependent upon the relative location of
the pacing site and site of CCM stimulation. ERP was shortened during
Fig. 3. Role of ganglionic transmission in the acute ventricular effects of CCM. A) Raw data illustrating instantaneous left ventricular pressure (LVP) and heart rate (HR) during right vagus
nerve stimulation (RVNS, 5Hz, 5 V) in the absence (left) and presence of 0.5 mM hexamethonium (right). B) Mean data representing the bradycardia effect of RVNS in the absence and
presence of hexamethonium (n = 3). C–E) Mean data demonstrating the change in LVP (C), rate of pressure production (dPdtmax, D) and basal MAPD90 (E) during basal CCM in the
absence and presence of hexamethonium (n = 5). Key: BL = baseline, SS = steady state, CCM= cardiac contractility modulation. Baseline vs. stimulation (VNS or CCM); *P b 0.05,
**P b 0.01, ***P b 0.001.
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but not apical regions (far from) (Fig. 5Diii). Similarly there was a trend
for ERP shortening, during LV endocardial pacing, with CCM applied inFig. 4. Effect of exogenous acetylcholine on the acute ventricular response to CCM. A) Raw dat
exogenous acetylcholine (ACh, 1 μM) and ACh + atropine (0.1 μM) perfusion associatedwith
action potential duration (MAPD90) in the absence and presence of ACh and ACh + atropine (napical (close) but not basal regions (far) (Fig. 5Dii, P = 0.07). No effect
of CCM on ERP was seen during RV endocardial pacing with either
basal or apical stimulation (Fig. 5Di).a illustrating left ventricular pressure (LVP) and peak LVP in the absence and presence of
basal CCM. B & C)Mean data demonstrating the change in peak LVP and basal monophasic
= 4). Difference in CCM response between experimental conditions; *P b 0.05, **P b 0.01.
Fig. 5. The effect of CCM on the ventricular ﬁbrillation threshold and ventricular dispersion of monophasic action potential duration. A) Mean data showing ventricular ﬁbrillation threshold
(VFT) at baseline (BL) and during CCM at basal and apical sites during RV endocardial, LV endocardial and LV epicardial pacing. B) Mean data illustrating monophasic action potential
duration (MAPD90) at BL and during CCM. C) Maximum–minimum MAPD90 at BL and with CCM. D) Effective refractory period (ERP) at baseline and during CCM E) The correlation
between Max–Min MAPD90 vs. VFT (regression ﬁt represents combined datasets, with the exception of (Eiii) in which basal CCM data points are excluded (dotted line)). Comparison
to baseline; *P b 0.05, **P b 0.01, ***P b 0.001, base vs. apex; #P b 0.05, ##P b 0.01 (VFT, MAPD; n = 8, ERP; n = 4, same hearts).
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Mean data on the effect of CCM onMAPD90 andmax-min dispersion
are presented in Fig. 5B & C. Un-stimulated MAPD90 was similarbetween basal and apical regions during RV and LV endocardial pacing
but longer in basal, vs. apical, regions during LV epicardial pacing
(Fig. 5B). CCM caused signiﬁcant shortening of MAPD90 close to the
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icant increase of max-min MAPD90 (Fig. 5C) (n = 8). The increase in
dispersion of repolarisation was similar during apical and basal CCM
and occurred in all pacing protocols (Fig. 5C). The scatterplots presented
in Fig. 5E show that VFT was inversely correlated with max-min
MAPD90 during RV endocardial (5Ei) and LV endocardial (5Eii), but
not LV epicardial (5Eiii), pacing. It is apparent that the reduction in
VFT with basal CCM, during LV epicardial pacing, may be the product
of increased MAPD90 dispersion and shortening of ERP at the site of
CCM stimulation. Analysis of LV epicardial pacing, when basal CCM
data are removed from the dataset, reveals a trend of correlation be-
tween VFT and max-min MAPD90 dispersion (Fig. 5Eiii), similar to that
seen with LV and RV endocardial pacing.
Perfusion of metoprolol abolished the shortening of MAPD90 during
basal (131 ± 4 [Metoprolol + Basal CCM] vs. 128 ± 2 [Metoprolol]
ms) and apical CCM (132 ± 4 [Metprolol + Apical CCM] vs. 129 ± 5
[Metoprolol] ms). Max-min MAPD90 dispersion during CCM stimu-
lation with metoprolol was similar to baseline values (4.7 ± 2.0
[Metoprotol + Basal CCM] vs. 4.2 ± 1.7 [Metoprolol]ms) (RV endocar-
dial pacing, n = 6).
3.4. AP dynamics and spatial electrophysiological effects of CCM
3.4.1. Optical vs. contact
Optical action potentials (n = 4) recorded at baseline under un-
stimulated conditions were signiﬁcantly longer than those recorded
with contact electrodes (RV endocardial pacing, n = 8) in both basal
(159 ± 6 [Optical] vs. 131 ± 6 [Contact] ms, P b 0.01) and apical
(169 ± 6 [Optical] vs. 133 ± 6 [Contact] ms, P b 0.01) regions. Optical
recordings were associated with a signiﬁcant apico-basal dispersion of
APD90 (169 ± 6 [Apex] vs. 159 ± 6 [Base] ms, P b 0.01) not present
in contact electrode recordings (133 ± 6 [Apex] vs. 131 ± 6 [Base])
and attributable to the adverse electrophysiological effects of blebbistatin.
3.4.2. AP Dynamics
Raw and mean data demonstrating time dependent adaptation of
ventricular APD during LV free wall CCM are presented in Fig. 6. APs
were recorded close to the site of CCM stimulation (within 2 mm).
Despite a clear deﬂection attributable to the CCM stimulus (Fig. 6),
there was no instantaneous effect on APD90. Rather, APD shortenedFig. 6. Temporal changes in action potential duration during local CCMstimulation. A) Example
action potentials demonstrating the effects of CCM on action potential duration (APD90)
on the ﬁrst beat, and after 10–30 s of stimulation (optical). B) Mean data demonstrating
the time course of APD90 changes during local CCM stimulation. CCM vs. baseline;
***P b 0.001 (n = 3).over a period of seconds with a maximal response at 30 s. Responses
recovered to baseline 2–3 min after cessation of stimulation (data not
shown).
3.4.3. Spatial effects of CCM
Raw and mean data demonstrating the effect of CCM on optically
recorded APs are illustrated in Fig. 7A. In accordance with data obtained
from contact electrodes, CCM caused APD shortening close to the stim-
ulation site, but not at recording sites distant to CCM stimulation. Raw
data illustrating the spatial spread of optical AP shortening during
high amplitude basal CCM is shown in Fig. 7.and shows that the degree
of APD shortening decays relatively uniformly away from the stimula-
tion site. The range of APD shortening appears greater during basal
CCM as deﬁned by distance from site of stimulationwhen APD shorten-
ing fails to reach statistical signiﬁcance (Fig. 7C-D, n = 4).
4. Discussion
To the best of our knowledge, this is the ﬁrst study to demonstrate
that CCM (20 mA, 20 ms) increases susceptibility to ventricular ﬁbrilla-
tion, an effect that is dependent on β1-adrenoceptor activation and is
associated with an increase in ventricular APD dispersion. In addition,
we have shown that the ventricular effects of CCM are abolished during
the perfusion of exogenous ACh but unaffected during muscarinic re-
ceptor antagonism and ganglionic blockade, suggesting that local intra-
cardiac/spinal reﬂex pathways are not involved. These data support the
notion that the acute effects of CCM are mediated through local release
of NE from post-ganglionic sympathetic nerves.
4.1. Recruitment of intracardiac/intrathoracic ganglia
Intracardiac and intrathoracic ganglia have been shown to be in-
volved in the beat-to-beat control of ventricular performance indepen-
dently from the central nervous system [6]. The electrical current used
during CCM should be sufﬁcient to activate ventricular afferent ﬁbres,
as suggested by experiments using electrical stimulation to identify
sympathetic afferents [12], and thus a proportion of the CCM response
may occur through ganglionic activation and recruitment of additional
efferent sympathetic inputs. We investigated this hypothesis using the
ganglionic neurotransmission inhibitor hexamethonium. Although
hexamethonium abolished the bradycardic response to vagal nerve
stimulation it had no effect on the acute ventricular responses to CCM.
These data demonstrate that the effects of CCM occur solely through
the electrical stimulation of post-ganglionic sympathetic ﬁbres that
innervate the ventricle.
4.2. The role of acetylcholine
We conﬁrm our previous ﬁnding that CCM increases ventricular
contractility and shortens MAPD through β1-adrenoceptor activation
following NE release [4]. These data are supported by studies demon-
strating the adrenergic dependence of CCM in the goat and dog [13].
In the present study we investigated whether ACh, released from para-
sympathetic nerves with the ventricle, plays any role in the acute action
of CCM.
It is well known that the vagus nerve antagonises the action of the
sympathetic nervous system. Binding of NE to the β−adrenoceptors
increases the activity of soluble adenylyl cyclase, catalysing the forma-
tion of cAMP, which activates protein kinase A to phosphorylate several
protein targets increasing contractile force. ACh binds to muscarinic
receptors reducing the release of NE from sympathetic nerves and
inhibits the formation of cAMP within cardiac myocytes [14,15]. It is
reasonable to assume that exogenous ACh perfusion prevents the
acute actions of CCM through a combination of these mechanisms. In
much the sameway that CCM stimulates sympathetic nerves, parasym-
pathetic nerves can also be stimulated. Despite substantial functional
Fig. 7. The effects of CCM on action potential duration across the anterior ventricular surface. A) Raw data demonstrating optically action potentials recorded at base and apex regions at
baseline (BL) and during basal and apical CCM. B) The spatial spread of APD shortening during basal CCM from a representative experiment. D & E)Mean data demonstrating the effective
range of APD shortening from the site of CCM delivery. Dotted lines denote the statistical cut off for each data set. (n = 4).
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cle, atropine failed to modify the ventricular CCM response, suggesting
that there was insufﬁcient ACh release from tentative parasympathetic
nerve stimulation to modulate the adrenergic component of CCM.
4.3. Calcium vs. hormone hypothesis
CCM was initially proposed as a technique to increase cardiac con-
tractility through direct modulation of calcium entry during the action
potential (calcium/electrotonic hypothesis). However, our data demon-
strate that application of CCM signals to the ventricle stimulates the
release of NE from sympathetic nerves [4], which acts upon the myocardi-
um through classical β-adrenoceptor signalling pathways. This hormone
hypothesis is supported by the results of the present study, in that both
metoprolol and ACh abolished the ventricular reponses to CCM. Moreover,the positive intotropic response and shortening ofMAPDduring CCMare in
keeping with adrenergic activation. Although we did not perform experi-
ments with calcium channel blockers, the lack of response to CCM during
both metoprolol and ACh perfusion indicates that its effects on calcium, as
seen in other studies [16], are secondary to adrenergic activation.
Initial experiments describing an electrotonic modulation of action
potential duration by CCMwere performed in the isolated rabbit papil-
lary muscle and utilised unipolar ﬁeld stimulation. These studies dem-
onstrate that cathodic and anodic electrical stimulation have opposing
inﬂuences on force and APD, presumably due to an accumulation of
electrical charge at the stimulating electrode and resultant modulation
of membrane potential and L-type calcium current. However, the
electrotonic hypothesis predicts that opposing effects would be exerted
at the anodal and cathode electrodes and that the net change in con-
tractility during bipolar CCM could be zero (if all regions respond
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should exert equal depolarising and hyperpolarising inﬂuences at
each electrode. The electrotonic hypothesis does not provide adequate
explanation for the effects of CCM in whole heart and the lack of any
immediate contractile effects in whole heart studies provides support
for the hormone hypothesis [4,16]. Moreover, we have previously
shown that CCM does not exert any effect on ventricular force during
β-adrenoceptor blockade [4]. In the present study we show, using opti-
cal mapping, that biphasic CCM signals do not prolong the action poten-
tial but that APD shortens over a period of seconds, in keeping with the
dynamics of adrenergic stimulation [17].
4.4. Regional electrophysiological response to CCM
We have previously shown that the CCM induced APD shortening
was partially mediated by activation of the slow delayed rectifying
potassium current (IKs) [4]. Ourﬁndings are in keepingwith the classical
effects of sympathetic activation on ventricular electrophysiology and
are supported by other studies reporting the adrenergic dependence
of CCM [13]. In the present study we conﬁrm localised APD shortening
during CCM, close to the stimulation site but not in regions that are
distant. The mechanisms whereby CCM exerts a greater functional
effect during basal CCM and apparently “captures” a greater region is
not known although it is plausible that this reﬂects either the pattern
of sympathetic innervation, ion channel distribution and/or the effect
of coronary circulation. We have previously reported a greater expres-
sion of tyrosine hydroxylase, a surrogate marker of sympathetic nerve
distribution, at basal LVmyocardium of the rabbit [18]. Other investiga-
tors have reported a graded distribution of catecholamines and sympa-
thetic nerve ﬁbres frombasal to apical regions [19,20]. It is reasonable to
hypothesise that CCM captures a larger number of sympathetic nerves
when applied to the basal myocardium. Although we have not mea-
sured NE release in the present study we would expect that to see a
greater NE release during basal CCM than with apical CCM based
on the physiological parameters. We have previously shown that NE
release during CCM is dependent upon the current amplitude applied
to the basal LV, likely reﬂecting “capture” of a greater area of the LV
and thus sympathetic nerves [4]. The expression of KCNQ1, the pore
forming protein subunit responsible for the adrenergic sensitive slow
delayed rectiﬁer potassium current, is also higher at the base than the
apex [18]whichmay also contribute to the greater degree of APD short-
ening with CCM at the base. It is also possible that the greater distance
range of CCM induced shortening during basal stimulation reﬂects the
downstream coronary circulation transporting NE away from its release
site deeper and further away from the stimulation site. Because of the
location, NE release in apical regionswill be distributed to a smaller pro-
portion of the myocardium via coronary circulation.
4.5. CCM and ventricular arrhythmias
In the present study we show that CCM signals (20 mA, 20 ms),
applied to the LV epicardial surface of the normal rabbit heart, promote
localised action potential shortening and give rise of non-uniformities of
APD across the ventricular surface. We demonstrate that CCM increases
apico-basal APD dispersion in a manner correlated with a downward
shift in VFT and dependent upon b1-adrenoceptor stimulation (being
abolished by metoprolol). Furthermore, ERP is substantially shortened
at the site of CCM stimulation and appears to contribute to the pro-
arrhythmic phenotype, causing a greater reduction in VFT when com-
pared to the effects of MAPD90 dispersion alone. It is probable that the
localised effects of CCM contribute to electrical instability during rapid
pacing and that this underpins an increase in VF susceptibility. It is
well known that spatial repolarisation heterogeneity provides an ideal
substrate for the generation of ventricular arrhythmias [21]. Dispersion
of APD is a known pro-arrhythmic mechanism underlying circus move-
ment re-entry around refractory regions [22] and computational studiesdemonstrate a key role of APD dispersion in the genesis and propogation
of VF [23].
4.5.1. Clinical implications
Our data demonstrate that CCM increases the susceptibility of the
crystalloid perfused rabbit heart to experimentally induced VF, however
it is recognised that the present study utilises healthy non-disease
animal hearts and as suchwe are cautious of offering direct correlations
with clinical application of CCM therapy in human heart failure. Further
study in animal models of heart failure, failing human tissue and pro-
spective clinical studies would be necessary to conﬁrm our results. It
is clear that CCM signals of ±20 mA and 20 ms applied to the rabbit
heart may not be directly comparable to the application of similar or
smaller amplitude signals in the larger canine or human heart and
these values were selected from our previous experience and not as a
comparison to clinical CCM. Nevertheless, the observed effects on action
potential dispersion, regional repolarisation andVFTmaybe of scientiﬁc
and clinical interest.
Anecdotal evidence from clinical studies of CCM suggests that there
is no increase in the number of serious adverse arrhythmic events with
CCM. However these trials are relatively small in size, short in duration
and do not provide any record on the occurrence of arrhythmic events
i.e. number of premature ventricular beats, non-sustained VT events,
other than those presenting in clinic i.e. sustained VT and VF [2]. Several
factors including the intermittent nature of chronic CCM therapy (4–6 h
per day), the interaction of CCMwith long-term beneﬁcial remodelling,
and the use of β-blockers may inﬂuence the occurrence of arrhythmias
in vivo. Exercise regimes, like CCM, are associated with intermittent
sympathetic activation and are widely accepted to improve patient
quality of life without affecting mortality and hospitalisation rates
(during a 4 year follow up period) [24]. It is attractive to suggest that
CCM, which is commonly applied intermittently for 4–6 h per day,
mimics the effects of daily exercise; however exercise will have many
additional effects other than an increased sympathetic tone.
Whilst exercise regimes and CCM are both adrenergic in nature, it
should be noted that clinical studies of CCM have been carried out in
patients on β-blockers. Although the degree of β-blockade cannot be
accurately assessed in each patient, there is the possibility that the
level of β-blockade present could counteract at least in part the adverse
effects of CCM on arrhythmogenesis. Complete β-adrenoceptor
blockade is unlikely to be achieved clinically due to the association
with signiﬁcant side effects with potentially high doses. Rather the
goal of β-blockade therapy in heart failure is to reduce sympathetic
over-activation. CCM has been shown to be effective (acutely and
chronically) in patients receiving β-blockade drugs [2]. It cannot be
ruled out that the long-term beneﬁcial effects of CCM are not mediated
by β1-adrenoceptor signalling. It is equally plausible that the long-term
beneﬁcial effects of CCM in heart failure, for example upon molecular
remodelling, offer some protection from associated arrhythmias negat-
ing the negative inﬂuence of acute CCM therapy. It is clear thatmore de-
tailed study on the long-term mechanism of action of CCM is required,
with a special focus on the effects of long term CCM on spontaneous
ventricular arrhythmias and arrhythmias susceptibility.
4.6. CCM and ventricular relaxation
Aswith our previous study, CCM increased LVpressure development
and contractility but had little effect on ventricular relaxation. This
ﬁnding is in accordance with other reports [25]. We have previously
proposed [4] that the localised effects of CCM and the proportion of
sympathetic ﬁbres stimulated during CCMmay be insufﬁcient to signif-
icantly alter global relaxation. Relaxation is dependent upon both
calcium reuptake into the sarcoplasmic reticulum and the passive prop-
erties of themyocardium and as suchmaynot be a sensitive to the local-
ised effects of CCM. We cannot discount that there may be regional
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measure reported in our study.
4.7. Ventricular ﬁbrillation threshold
The susceptibility of the heart to VF was studied by measuring the
VFT, which is a quantiﬁable and reproduciblemeasure reﬂecting electri-
cal stability [7]. Despite controversy regarding its ability to predict the
effects of some anti-arrhythmic drugs, VFT has been shown to be a
powerful predictor of altered arrhythmia vulnerability in relation to
the autonomic nervous system [7,26].
4.8. Study limitations
4.8.1. Site of CCM delivery different to clinical use and comparisons with
larger species
We use epicardial LV sites for CCM delivery to ascertain the effects
and mechanisms underlying CCM. Importantly, this method is in accor-
dance with previous mechanistic studies in both the canine and ferret
[33,34]. Clinically, the site of CCM delivery chosen is the RV septum
[2], as it is convenient for and akin to standard cardiac device lead
placement. Whilst our study differs in this regard, other investigators
have reported that the effects of CCM are abolished by β-blockade dur-
ing stimulation of the RV septum of the goat [13], in accord with our
previouswork [4]. The localised electrophysiological effects of CCM sug-
gest that application in any region may promote heterogeneities of
repolarisation and provide a substrate for arrhythmia.
Histological studies suggest that there exists a transmural dispersion
of nerve distribution through the hearts, with less sympathetic innerva-
tion but more parasympathetic innervation of the ventricular endocar-
dium [20]. We cannot discount that epicardial CCM captures more
sympathetic ﬁbres than the endocardial approach used clinically and
that this will inﬂuence the change in VFT with CCM.
Although the spacing between our electrodes is proportionally sim-
ilar to that used in larger species (e.g. dogs and humans) we cannot
exclude that a 20 mA stimulus might stimulate a greater proportion of
the smaller rabbit heart in relation to larger hearts. Despite this, the
degree of inotropic enhancement is similar to that reported in other
studies [16,25]. The parameters of our CCM signal were selected on
the basis of our previous work characterising functional and electro-
physiological responses with varying signal amplitude, delay and dura-
tion [4].
4.8.2. Electromechanical uncoupling agent
During optical mapping we use the electromechanical uncoupler
blebbistatin to prevent cardiac movement during imaging. We have
recently reported that blebbistatin has a direct effect on ventricular
electrophysiological parameters prolonging APD and increasing resis-
tance to VF induction [27]. Due to the pronounced electrophysiological
effects of blebbistatin, data on the effects of CCM on VFT were not
collected in optical studies, rather these studies were used solely to
provide conﬁrmatory data on the regional inﬂuence of CCM, to comple-
ment our previously published ﬁndings [4] and add additional insight
into the spatial distribution and dynamics of CCM effects. The mecha-
nisms of action of blebbistatin's electrophysiological effects are not
clear and require further investigation.
5. Conclusions
To our knowledge, this study represents the ﬁrst direct investigation
of the effects of CCM on ventricular arrhythmia vulnerability. Our data
show that CCM (±20 mA, 20 ms) increases the vulnerability to ventric-
ular ﬁbrillation through a β1-adrenoceptor dependent mechanism and
is associated with APD shortening and an increase in APD dispersion
(in the crystalloid perfused rabbit heart). In conjunctionwith our previ-
ous study, we conclude that the acute effects of CCM are mediated viaNE release from efferent postganglionic sympathetic nerves as the
response to CCM can be abolished by exogenous ACh perfusion.Disclosures
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